Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences.

Karam, Susan L; Dendy, Jared; Polu, Shruti; Blonde, Lawrence

Karam, Susan L; Dendy, Jared; Polu, Shruti; Blonde, Lawrence.

Afiliação

Karam SL; Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA.
Dendy J; Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA.
Polu S; Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA.
Blonde L; Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA.

Diabetes Spectr ; 33(1): 8-15, 2020 Feb.

Article em En | MEDLINE | ID: mdl-32116448

ABSTRACT

ABSTRACT

Many people with diabetes do not achieve individualized treatment targets. Therapeutic inertia, the underuse of effective therapies in preventing serious clinical end points, is a frequent, important contributor to this failure. Clinicians, patients, health systems, payors, and producers of medications, devices, and other products for those with diabetes all play a role in the development of therapeutic inertia and can all help to reduce it.

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: Diabetes Spectr Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Laos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google